Compare Stocks: NXTC, PMVP, OKYO, and GOSS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$10.72 +0.6%	$12.85	$9.10 ▼ $309.60	$65.47M	2.21	241,033 shs	139,597 shs
NXTC NextCure	$5.63 +11.6%	$6.19	$1.55 ▼ $15.74	$20.35M	1.33	752,791 shs	105,713 shs
OKYO OKYO Pharma	$1.46 -0.7%	$1.49	$1.26 ▼ $3.20	$76.62M	0.05	144,495 shs	28,810 shs
PMVP PMV Pharmaceuticals	$1.61 -9.6%	$1.33	$1.02 ▼ $1.91	$86.07M	1.36	534,702 shs	517,586 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	-0.56%	-7.55%	-24.06%	-25.00%	-94.82%
NXTC NextCure	-0.79%	-0.59%	-35.42%	+183.71%	-11.94%
OKYO OKYO Pharma	0.00%	+7.30%	-6.37%	-16.00%	-28.29%
PMVP PMV Pharmaceuticals	-0.56%	+30.88%	+37.98%	+43.55%	+23.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$10.72 +0.6%	$12.85	$9.10 ▼ $309.60	$65.47M	2.21	241,033 shs	139,597 shs
NXTC NextCure	$5.63 +11.6%	$6.19	$1.55 ▼ $15.74	$20.35M	1.33	752,791 shs	105,713 shs
OKYO OKYO Pharma	$1.46 -0.7%	$1.49	$1.26 ▼ $3.20	$76.62M	0.05	144,495 shs	28,810 shs
PMVP PMV Pharmaceuticals	$1.61 -9.6%	$1.33	$1.02 ▼ $1.91	$86.07M	1.36	534,702 shs	517,586 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	-0.56%	-7.55%	-24.06%	-25.00%	-94.82%
NXTC NextCure	-0.79%	-0.59%	-35.42%	+183.71%	-11.94%
OKYO OKYO Pharma	0.00%	+7.30%	-6.37%	-16.00%	-28.29%
PMVP PMV Pharmaceuticals	-0.56%	+30.88%	+37.98%	+43.55%	+23.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOSS Gossamer Bio	2.22	Hold	$256.00	2,315.09% Upside
NXTC NextCure	2.25	Hold	$19.00	234.51% Upside
OKYO OKYO Pharma	2.50	Moderate Buy	$5.67	286.54% Upside
PMVP PMV Pharmaceuticals	2.80	Moderate Buy	$4.33	157.17% Upside

Current Analyst Ratings Breakdown

Latest NXTC, PMVP, OKYO, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/24/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOSS Gossamer Bio	$48.47M	1.34	N/A	N/A	($42.43) per share	-0.25
NXTC NextCure	N/A	N/A	N/A	N/A	$9.97 per share	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)
OKYO OKYO Pharma	-$8.95M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)

Latest NXTC, PMVP, OKYO, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOSS Gossamer Bio	N/A	0.53	0.53
NXTC NextCure	N/A	3.47	3.47
OKYO OKYO Pharma	N/A	2.43	2.43
PMVP PMV Pharmaceuticals	N/A	7.70	7.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOSS Gossamer Bio	81.23%
NXTC NextCure	42.65%
OKYO OKYO Pharma	2.97%
PMVP PMV Pharmaceuticals	90.20%

Insider Ownership

Company	Insider Ownership
GOSS Gossamer Bio	4.15%
NXTC NextCure	11.90%
OKYO OKYO Pharma	40.46%
PMVP PMV Pharmaceuticals	10.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOSS Gossamer Bio	162	6.11 million	5.86 million	Optionable
NXTC NextCure	40	3.61 million	3.18 million	No Data
OKYO OKYO Pharma	5	52.48 million	31.25 million	Not Optionable
PMVP PMV Pharmaceuticals	54	53.46 million	48.03 million	Optionable

NXTC, PMVP, OKYO, and GOSS Headlines

Recent News About These Companies

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

October 5 at 12:47 PM | finance.yahoo.com

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Rated "Moderate Buy" by Sell-Side Brokerages

September 29, 2026 | americanbankingnews.com

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts

September 29, 2026 | marketbeat.com

Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?

September 16, 2026 | zacks.com

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), PMV Pharmaceuticals (PMVP) and Tyra Bioscience (TYRA)

September 9, 2026 | theglobeandmail.com

PMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt Filing

September 9, 2026 | rttnews.com

PMV Pharma appoints Philip Herman as CCO

September 9, 2026 | thepharmaletter.comT

Brokers Issue Forecasts for PMVP Q3 Earnings

September 9, 2026 | marketbeat.com

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

September 8, 2026 | finance.yahoo.com

919,818 Shares in PMV Pharmaceuticals, Inc. $PMVP Acquired by BlackRock Inc.

September 7, 2026 | marketbeat.com

PMV Pharmaceuticals stock gains as biotech peers advance

September 5, 2026 | ad-hoc-news.deA

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

September 1, 2026 | finanznachrichten.de

PMV Pharma Posts Interim Phase 2 PYNNACLE Ovarian Cancer Data; Prices $50.8 Mln Offering; Stock Down

September 1, 2026 | rttnews.com

PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering

September 1, 2026 | finance.yahoo.com

PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants

August 31, 2026 | quiverquant.comQ

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

August 31, 2026 | globenewswire.com

PMV Pharma Announces Proposed Public Offering of Securities

August 31, 2026 | globenewswire.com

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

August 31, 2026 | globenewswire.com

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

August 19, 2026 | zacks.com

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 14, 2026 | globenewswire.com

PMV Pharmaceuticals, Inc.

August 13, 2026 | edition.cnn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, PMVP, OKYO, and GOSS Company Descriptions

Gossamer Bio NASDAQ:GOSS

$10.72 +0.07 (+0.61%)

Closing price 03:59 PM Eastern

Extended Trading

$10.78 +0.07 (+0.65%)

As of 04:04 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

NextCure NASDAQ:NXTC

$5.63 +0.58 (+11.56%)

Closing price 03:59 PM Eastern

Extended Trading

$5.80 +0.16 (+2.86%)

As of 04:04 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

OKYO Pharma NASDAQ:OKYO

$1.46 -0.01 (-0.68%)

As of 04:00 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

PMV Pharmaceuticals NASDAQ:PMVP

$1.61 -0.17 (-9.55%)

Closing price 03:59 PM Eastern

Extended Trading

$1.62 +0.00 (+0.31%)

As of 04:04 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NXTC, PMVP, OKYO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NXTC, PMVP, OKYO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NXTC, PMVP, OKYO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, PMVP, OKYO, and GOSS Company Descriptions

Gossamer Bio NASDAQ:GOSS

NextCure NASDAQ:NXTC

OKYO Pharma NASDAQ:OKYO

PMV Pharmaceuticals NASDAQ:PMVP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NXTC, PMVP, OKYO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NXTC, PMVP, OKYO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NXTC, PMVP, OKYO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, PMVP, OKYO, and GOSS Company Descriptions

Gossamer Bio NASDAQ:GOSS

NextCure NASDAQ:NXTC

OKYO Pharma NASDAQ:OKYO

PMV Pharmaceuticals NASDAQ:PMVP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools